ASTELLAS PHARMA
At Astellas, our vision is to be at the forefront of healthcare change by turning innovative science into meaningful VALUE for patients. As a specialty global pharmaceutical company, we focus on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. Together with our partners, we aim to lead in the areas where we can deliver the greatest value, with a focus on immuno-oncology, gene the... rapy, mitochondria, blindness and regeneration and targeted protein degradation. Astellas operates its business in approximately 70 countries around the world. It has approximately 14,000 employees, and its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation. In its FY2022 financial results, revenue achieved about 1,500 billion yen (ca.$11 billion*), and R&D expenses were about 280 billion yen (ca.$2.0 billion*). *The exchange rate for the yen, 1USD: 142yen
ASTELLAS PHARMA
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2005-04-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.astellas.com
Total Employee:
10001+
Status:
Active
Contact:
+81-3-3244-3000
Technology used in webpage:
Domain Not Resolving Apple Mobile Web Clips Icon Google Font API Google Maps LetsEncrypt Mobile Non Scaleable Content IPv6 Google Analytics 4 Google Google Cloud
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-12-21 | Propella | Propella acquired by Astellas Pharma | N/A |
| 2023-04-30 | IVERIC bio | IVERIC bio acquired by Astellas Pharma | 5.9 B USD |
| 2020-10-15 | Iota Biosciences | Iota Biosciences acquired by Astellas Pharma | 127.5 M USD |
| 2020-04-21 | Nanna Therapeutics | Nanna Therapeutics acquired by Astellas Pharma | 12 M GBP |
| 2019-12-26 | Xyphos Biosciences | Xyphos Biosciences acquired by Astellas Pharma | N/A |
| 2019-12-02 | Audentes Therapeutics | Audentes Therapeutics acquired by Astellas Pharma | 3 B USD |
| 2018-12-14 | Potenza Therapeutics | Potenza Therapeutics acquired by Astellas Pharma | 405 M USD |
| 2018-08-10 | Quethera | Quethera acquired by Astellas Pharma | 109 M USD |
| 2018-02-13 | Universal Cells Inc. | Universal Cells Inc. acquired by Astellas Pharma | N/A |
| 2017-12-01 | Mitobridge | Mitobridge acquired by Astellas Pharma | N/A |
Investors List
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Astellas Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-08-07 | Poseida Therapeutics | Astellas Pharma investment in Post-IPO Equity - Poseida Therapeutics | 50 M USD |
| 2022-10-24 | Taysha Gene Therapies | Astellas Pharma investment in Post-IPO Equity - Taysha Gene Therapies | 50 M USD |
| 2021-11-04 | The National Comprehensive Cancer Network (NCCN) | Astellas Pharma investment in Grant - The National Comprehensive Cancer Network (NCCN) | N/A |
| 2019-10-06 | LabCentral | Astellas Pharma investment in Corporate Round - LabCentral | 13 M USD |
| 2018-12-27 | Iota Biosciences | Astellas Pharma investment in Series A - Iota Biosciences | 15 M USD |
| 2017-11-15 | Catalia Health | Astellas Pharma investment in Grant - Catalia Health | 12.5 K USD |
| 2013-10-04 | Mitobridge | Astellas Pharma investment in Series A - Mitobridge | 5.22 M USD |
| 2012-04-24 | Telsar Pharma | Astellas Pharma investment in Series A - Telsar Pharma | 14 M USD |
| 2008-06-05 | CoMentis | Astellas Pharma investment in Series D - CoMentis | 20 M USD |
| 2005-02-17 | FibroGen | Astellas Pharma investment in Venture Round - FibroGen | 100 M USD |
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-05 | Chutes & Ladders—Astellas shakes up leadership with two new C-suite execs |
Official Site Inspections
http://www.astellas.com Semrush global rank: 218.11 K Semrush visits lastest month: 196.55 K
- Host name: 23.96.32.128
- IP address: 23.96.32.128
- Location: Washington United States
- Latitude: 38.7095
- Longitude: -78.1539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 22747
More informations about "Astellas Pharma"
Corporate Governance | Astellas Pharma Inc.
Astellas' Corporate Governance. We aim to sustainably enhance corporate value by being chosen and trusted by all stakeholders.See details»
Astellas Makes Announcement about Management Structure
Feb 4, 2025 Astellas aims to create and deliver "VALUE" for patients. To promote drug discovery activities swiftly and efficiently from the early stages of research through to commercialization …See details»
Astellas Pharma - The Org
Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on …See details»
Our Business | Astellas Pharma Inc.
Astellas conducts business in more than 70 countries and regions around the world, and in addition to complying with each country and region’s laws, …See details»
At a Glance | Astellas Pharma Inc.
The Astellas Group Corporate Information: We are expanding our business in more than 70 countries and regions worldwide.See details»
Astellas Pharma Org Chart + Executive Team - The Official Board
The org chart of Astellas Pharma contains its 88 main executives like Naoki Okamura, Atsushi Kitamura and Adam Pearson.See details»
Astellas Announces a Partnership with the "Korea Institute of …
Jul 17, 2025 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has agreed on a memorandum of understanding ("MoU") with the …See details»
Astellas Announces Management Structure
Feb 4, 2021 Astellas Announces Management Structure TOKYO, February 4, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today …See details»
Astellas Pharma - Wikipedia
Astellas Pharma office in Canada Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 …See details»
Astellas Pharma - Crunchbase Company Profile & Funding
Apr 1, 2005 When was the last funding round for Astellas Pharma? Astellas Pharma closed its last funding round on Jul 22, 2020 from a Grant round. Who are Astellas Pharma's …See details»
Sign In - Astellas Pharma
Please enter your Astellas username and password. Your Astellas username should be in the following format: <astellas username>@astellas.comSee details»
Astellas Makes Announcement about Management Structure
Feb 4, 2025 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.See details»
Astellas Makes Announcement about Management Structure
Feb 4, 2025 About Astellas Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease …See details»
Astellas Pharma - Leadership Team | The Org
The Leadership Team at Astellas Pharma plays a crucial role in shaping the company’s strategic direction and overseeing its operations. Comprising executives from various disciplines, …See details»
Request for Proposal for programs aligning with
The successful organization(s) will build and execute the program as outlined in their application and independent and without direction from Astellas. Astellas may support the cause with …See details»
Astellas Makes Announcement about Management Structure
Feb 6, 2024 About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area …See details»
Astellas Pharma Canada - Markham Business
Apr 2, 2025 Astellas Canada is celebrating 20 years of life-changing medical research and development in 2025. The pharmaceutical company was formed in 2005 with the merger of …See details»
Astellas Pharma | LinkedIn
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, …See details»
Astellas Pharmaceutical
Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., with its headquarters located in Northbrook, Illinois. A northern suburb of Chicago, the campus …See details»
Astellas Global Health Foundation
The Astellas Global Health Foundation: Dedicated to Improving Access to Health, Building Resilient Communities and Providing Disaster Support in Underserved Global Communities …See details»